Strong efficacy and a clean safety profile – with no cardiovascular signal – in another Phase III study bode well for filings of Zogenix's ZX008 in the fourth quarter.
Zogenix Inc.'s latest Phase III data for ZX008 (low dose fenfluramine) in the rare childhood epilepsy Dravet syndrome suggest the drug has a stronger profile compared with GW Pharmaceuticals PLC's recently approved cannabinoid drug Epidiolex.
There are some 8,000 Dravet syndrome patients in the US and up until recently no treatments were
AbbVie chief commercial officer Jeffrey Stewart called Trump’s drug pricing plan a “disruption” but said ultimately the delta between US and EU drug prices may not be as high as some expect.
At the Bank of America health care conference, pharma leaders speculated on what Trump’s executive order on drug pricing could mean for US and European drug prices.
The acquisition of Boston Pharma’s once-a-month FGF21 analog adds to GSK’s liver disease portfolio.
